Once-daily fingolimod 0.5 mg (FTY720; Gilenya®, Novartis Pharma AG, Basel, Switzerland) is a sphingosine 1-phosphate receptor modulator that is approved for the treatment of relapsing multiple sclerosis (MS); currently, this includes approval in 13 Latin American countries.
Fingolimod (FTY720; Gilenya®, Novartis Pharma AG, Basel, Switzerland) is a first-in-class, orally administered sphingosine-1 phosphate receptor (S1PR) modulator that is approved for the treatment of relapsing forms of multiple sclerosis (MS) [ 1].
In fact, the only agent closest to a translation modulator that is approved for clinical use is a derivative of rapamycin, which inhibits TOR, a component of the PI3K signaling pathway that impinges upon ribosomal protein S6 and initiation of translation (Ciuffreda et al., 2010; Dancey, 2010).
The first calcimimetic drug is cinacalcet, a positive allosteric modulator of the CaSR that is approved for treating secondary hyperparathyroidism (HPT) in patients on renal replacement therapy and for some forms of primary HPT characterized by clinically significant hypercalcemia.
Lamotrigine, a modulator of glutamate release via its action on sodium and calcium channels, is approved for relapse prevention in bipolar disorder in the United States, and may have antidepressant properties in unipolar patients.
The validation of the model is approved.
Only riluzole is approved for ALS treatment.
However, currently, none of the ABCB1 inhibitors or modulators have been approved for clinical oncological practice.
Various bisphosphonates and the selective estrogen receptor modulator (SERM) raloxifene are approved treatments of postmenopausal osteoporosis.
Biologic agents targeting specific immune cells, such as modulators of B cell and T cell activity, were approved for RA patients not responding adequately to oral DMARDs or other biologic agents.
